CancerSEEK screens for cancers that account for more than 60 percent of U.S. cancer deaths. Image shows 3-D representation of cancer cells.
Johns Hopkins researchers have developed a unique, noninvasive blood test that detects proteins and gene mutations from eight common cancers. The test, called CancerSEEK, screens for cancers that account for more than 60 percent of U.S. cancer deaths.
Published in the journal Science in early 2018, the research studied blood samples from more than 1,000 patients with nonmetastatic, stages I to III cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung or breast. The median overall sensitivity, or the ability to find cancer, was 70 percent and ranged from a high of 98 percent for ovarian cancer to a low of 33 percent for breast cancer.
For the five cancers that have no screening tests—ovarian, liver, stomach, pancreatic and esophageal cancers—sensitivity ranged from 69 percent to 98 percent. The test was performed on 812 healthy people and produced only seven false-positive results.
The investigators initially explored a number of genes and 40 protein markers before whittling that number down to segments of 16 genes and eight proteins. They point out that this molecular test is solely aimed at cancer screening and, therefore, is different from other molecular tests, which on analyze much larger numbers of cancer-driving genes to identify therapeutically actionable targets.
“This has the potential to substantially impact patients. Earlier detection provides many ways to improve outcomes.” —Anne Marie Lennon
Although the current test does not pick up every cancer, it identifies many cancers that would likely otherwise go undetected. “Many of the most promising cancer treatments we have today only benefit a small minority of cancer patients, and we consider them major breakthroughs. If we are going to make progress in early cancer detection, we have to begin looking at it in a more realistic way, recognizing that no test will detect all cancers,” says co-author Bert Vogelstein, Ludwig Center director and Johns Hopkins professor of oncology and pathology.
“This test represents the next step in changing the focus of cancer research from late-stage disease to early disease, which I believe will be critical to reducing cancer deaths in the long term,” says Vogelstein.
The investigators feel that a test that could be used for cancer screening must be affordable, and envision that if widely used for screening the CancerSEEK test could eventually cost less than $500.